Assessment of acute asthma severity in the ED: are heart and respiratory rates relevant? - 31/07/15
Cet article a été publié dans un numéro de la revue, cliquez ici pour y accéder
Abstract |
Background |
Assessment of acute asthma severity in the emergency department (ED) determines the appropriate initial therapy. The aim of this study was to evaluate the usefulness of heart and respiratory rates as determinants of severity of asthma exacerbations.
Methods |
It was a pooled analysis of individual patient data from different controlled clinical trials performed over a 9-year period. The sample was characterized by patients with a diagnosis of asthma, age 18 to 50 years, and a forced expiratory volume in the first second (FEV1) or a peak expiratory flow less than or equal to 50% of predicted at ED presentation.
Results |
One thousand one hundred ninety-two severe acute asthmatics (age 33.9 ± 10.3 years and FEV1 = 27.4% ± 9.7%) were enrolled. Two-thirds of patients were categorized as having severe acute asthma (FEV1, 31%-50% of predicted) and the remaining third as life-threatening asthma (FEV1, ≤30% of predicted). There were no relationships between the intensity of airway obstruction as measured by the FEV1 and the degree of tachycardia (r = 0.05, P > .1) or tachypnea (r = 0.06, P > .1). Only 22% and 19% of the patients, respectively, met the heart rate and respiratory rate requirements for acute severe asthma (≥120/min and ≥25/min, respectively). In contrast to FEV1 and arterial oxygen saturation, baseline heart and respiratory rates did not predict admissions of patients at the end of treatment.
Conclusions |
This pooled analysis suggests a poor performance of heart and respiratory rates as determinants of acute asthma severity in the ED.
Le texte complet de cet article est disponible en PDF.Plan
☆ | Author disclosures of conflicts of interest: Drs Rodrigo and Neffen have no financial or other potential conflicts of interest related with the objective of this research. |
☆☆ | Funding source: No sponsorship from institutions or pharmaceutical industry was provided to conduct this study. |
Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.
Déjà abonné à cette revue ?